Ms Jayne Doran


Assistant Director for Regulatory Affairs, Team Leader for Early Drug Development

School of Cancer Sciences

Contact details

Telephone +44 (0) 121 414 6788

Fax +44(0) 121 414 3529


Cancer Research UK Clinical Trials Unit (CRCTU)
School of Cancer Sciences
Sir Robert Aitken Building
College of Medical and Dental Sciences
University of Birmingham
B15 2TT


Jayne Doran is one of the non-clinical Assistant Directors and team leader for the Early Drug Development team based within the Cancer Research UK Clinical Trials Unit (CRCTU).

She has responsibility to manage the financial and human resources of a multi-disciplinary trials team so as to ensure that the management and conduct of a portfolio of research protocols is effective, efficient and complies with all regulatory and quality standards. 

An important element of her role is to support and advise clinical investigators and senior science researchers in their endeavour to translate their initial ideas into clinical science, and ultimately into a clinical trial setting. She regularly acts as a representative for CRCTU on issues relating to early drug development and research governance.


Jayne started her career training as a Biomedical Scientist within the specialism of clinical biochemistry and worked within the NHS at a number of hospitals for almost 13 years. The role developed and culminated with her performing a research project at the then, Birmingham Women’s Hospital, developing and introducing a West Midlands regional screening programme for antenatal screening for Down’s Syndrome and other autosomal trisomies. A post within the University of Birmingham followed, and a career in clinical research began in earnest, which has continued and developed to the post she now holds. Throughout her career she has had the opportunity to contribute to local and national research policy, including the NCRI’s UK Cancer Plan and being part of the team responsible for developing and introducing the University’s clinical research sponsorship model. Her particular research interest is that of early experimental oncology and especially enjoys the collaborative nature of her work, particularly the interaction with the scientific community and the excitement of seeing an idea coming to fruition as a cancer therapy for patients. Outside of work Jayne is the proud mother of three sons and has recently embarked on her new role of doting grandmother to the most beautiful baby girl.


  • MSc in Clinical Oncology – Clinical Trials module
  • Intercalated BMedSci in Clinical Sciences – Research Methodology module


Research themes

  • Cancer Clinical Trials

Research Activity

  • Oversight of a portfolio of early phase oncology clinical trials and translational studies exploring the use of novel therapeutics and paradigms including, but not restricted to, small molecules and cellular therapies.

Other activities

  • Member of Genetic Modification Safety Committee UHBFT (to-date)
  • Member of CR UK Research Governance Working Group (to-date)
  • Member of NCRI Heads of Trials Unit Committee (to-date)
  • Member of UK CRC Experimental Medicine Website Working Group 
  • Member of the Experimental Cancer Medicine Centre (ECMC) steering committee (to-date)
  • Member of the NIHR –BRU Steering Committee (to-date)
  • Consultancy to external academic researchers and biotech companies (to-date)


G.S.Cruikshank, D.Ngogo, A.Detta, S.Green, N.D.James, C.Wojnecki, J.Doran, J.Hardie et al. (2009) A cancer research UK pharmacokinetic study of BPA-mannitol in patients with high grade glioma to optimise uptake parameters for clinical trials of BNCT. Applied Radiation and Isotopes 67S31-S33

NTRAC Report June 2005 Managing Commercial Trials in the NHS: Lessons from Cancer – Report compiled for Department of Health review to facilitate UK strategy.

Joint NTRAC and Cancer Research UK Report December 2003 QA in the laboratory, ways forward on good clinical and laboratory practice for early phase academic trials in the UK – Informative report for the MHRA to facilitate them as they develop national guidance and assessment criteria.

Leonard W Seymour, David R Ferry, David Anderson, Stuart Hesslewood, Peter J Julyan, Richard Poyner, Jayne Doran Annie Young, Sally Birtles and David Kerr for the Cancer Research Campaign Phase I/II Clinical Trials Committee(March 15), 2002. Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin Journal of Clinical Oncology, Vol 20, No 6:pp 1668-1676

Ferry DR, Deakin M, Baddeley J, Daryanani S, Bramhall S, Anderson DA, Wakelam MJO, Doran J, Pemberton G, Young AM, Buckels J, Kerr DJ 2001. A Phase II Study of the 5-Lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with Pharmacokinetic and Pharmacodynamic endpoints. Annals of Oncology 11:1165-1170, 2000

Julyan PJ, Seymour LW, Ferry DR, Daryanani S, Boivin CM, Doran J, David M, Anderson D, Christodoulou C, Young AM, Hesslewood S, Kerr D. 1998 Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. Journal of Controlled Release 57 (1999) 281-290.

Christos V.Christodoulou,David R. Ferry, David W. Fyfe, Annie Young, Jayne Doran, Ted Sheehan, Aristedes Eliopoulos, Keith Hale, Joachim Baumgart, Gretal Sass, David J. Kerr. 1998 Phase I Trial of Weekly Scheduling and Pharmacokinetics of Titanocene Dichloride (TD). Journal of Clinical Oncology Vol6, No8 (August) 1998:pp2761-2769

Back to top